Abstract: Mammalian metabilites of the known acetylchloinesterase inhibitor trimethyl-1,3a,8-hexahydro-1,2,3,3a,8,8a-pyrrol[2,3-b]indole-5(3aS,8aR) heptylcarbamate are themselves cholinesterase inhibitors useful in the treatment of various memory dysfunctions characterized by a cholinergic deficit such as Alzheimer's disease and are also useful as analgesic agents in the alleviation of pain.

Abstract: Synthetic antigens related to luteinizing hormone-releasing hormone (hereinafter designated LH-RH) having the amino acid composition, pyroglutamyl-histidyl-tryptophanylseryl-tyrosyl-glycyl-leucyl-arginyl-prol yl-glycyl-poly-L-lysine (hereinafter designated pyroglu-his-trp-ser-tyr-glyleu-arg-pro-gly-poly-L-lys) and poly-L-lysyl-glutarylhistidyl-tryptophanyl-seryl-tyrosyl-glycyl-leucyl-arg inylprolyl-glycine amide (hereinafter designated poly-L-lysglutaryl-his-trp-ser-tyr-gly-leu-arg-pro-gly) are prepared by coupling the corresponding decapeptide with poly-L-lysine. The corresponding decapeptides are prepared by controlled stepwise procedures starting with individual amino acid components. These antigens have the property of inducing formation of antibodies to luteinizing hormone-releasing hormone (LH-RH) in animals.